Full Press Release Details
Purpose-built for physicians
Read more
• LinkedIn
• Facebook
• X (Twitter)
• Bluesky
• Threads
• Email
• Copy Link
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David Kirn , MD, of 4D Molecular Therapeutics provides an update on two candidates for retinal diseases.
4D-150 demonstrated positive safety, retinal anatomy and durability results, as well as a reduction in the need for annualized anti-VEGF injections in patients with wet age-related macular degeneration, in the PRISM phase 2 clinical trial , he said.
The company has also filed an investigational new drug application for 4D-175 for the treatment of geographic atrophy.
“The next step in our development of these programs is to initiate phase 3 in Q1 of next year in wet AMD with 4D-150,” Kirn said. “We’ll also report out our first [diabetic macular edema] data in Q4 of this year in high-need DME patients.”
Sources/Disclosures
Source:
Healio Interviews
Disclosures: Kirn reports being co-founder and CEO of 4D Molecular Therapeutics.
Ask a clinical question and tap into Healio AI's knowledge base.
• PubMed, enrolling/recruiting trials, guidelines
• Clinical Guidance, Healio CME, FDA news
• Healio's exclusive daily news coverage of clinical data
Read more about